Broad-based population screenings as the parent comment suggests, in my opinion, are.
I'm yet to see any clinically-valid distinguishing aspects that would suggest AI would add value to screening. Curious to hear evidence that drives your optimism of human+AI.
Just to state, the NELSON study [1] focuses on high-risk segments. Their paper also recommends a "personalized risk-based approach" to screening. This seems reasonable.
Broad-based population screenings as the parent comment suggests, in my opinion, are.
I'm yet to see any clinically-valid distinguishing aspects that would suggest AI would add value to screening. Curious to hear evidence that drives your optimism of human+AI.
Just to state, the NELSON study [1] focuses on high-risk segments. Their paper also recommends a "personalized risk-based approach" to screening. This seems reasonable.
[1] https://www.nejm.org/doi/full/10.1056/nejmoa1911793